Leading weight loss drug developers Eli Lilly (NYSE:LLY), Novo Nordisk (NVO), and Amgen (NASDAQ:AMGN) are scheduled to present major clinical trial readouts at the American Diabetes Association’s (ADA) 85th Scientific Sessions taking place June 20-23 in Chicago.
Lilly (NYSE:LLY) is set to post results for its investigational oral weight loss therapy, orforglipron, from its ACHIEVE-1 Phase 3 trial for adults with type 2 diabetes at an ADA-sponsored symposium on June 21.
The Indiana-based drugmaker released topline data from ACHIEVE-1 in April, noting that the global trial, the first of seven Phase 3 studies for orforglipron, reached the main goal as the once-daily pill cut patients’ weight by ~8% on average over 40 weeks.
Novo Nordisk (NVO) is also set for a symposium presentation to release data from its REDEFINE 1 and REDEFINE 2 Phase 3 trials for its next-gen weight loss therapy, CagriSema on June 22.
Shares of the Danish drugmaker plunged in December after the once-weekly injectable fell short of the company’s initial expectations in its REDEFINE 1 Phase 3 trial, which enrolled obese or overweight adults with one or more associated illnesses.
“The presentation of the CagriSema REDEFINE 1 and 2 trials are the first ever Phase 3 data presented on a GLP-1 and amylin receptor agonist combination, offering insights into the potential of this investigational medicine,” the company said ahead of the event.
Meanwhile, the safety of Amgen’s (NASDAQ:AMGN) experimental weight loss therapy MariTide will be in focus when the Thousand Oaks, California-based firm shares full data from a Phase 2 study for the injectable on June 23.
Amgen (NASDAQ:AMGN) shares fell in November after the company reported that MariTide caused an average weight loss of up to 20% over 52 weeks. in the trial, which enrolled individuals with obesity or overweight conditions but without Type 2 diabetes.
Previously, a report from Cantor Fitzgerald indicated that a potential loss of bone mineral density could be a safety risk linked to MariTide, which targets gut hormone receptors (GLP-1) as well as glucose-dependent insulinotropic polypeptide receptors.
Other notable weight loss drug developers selected for ADA presentations include Altimmune (ALT), Metsera (MTSR), and Vertex Pharmaceuticals (VRTX).
More on Eli Lilly, Novo Nordisk, etc.
- Verve: Eli Lilly Acquisition Based On One-Time GalNAc PCSK9 Gene Editing Program
- Eli Lilly Buys Verve Therapeutics: Aims To Permanently Lower Your Cholesterol
- Verve Therapeutics’ Lifeline: Eli Lilly’s $1.3 Billion Bet On Cardiovascular Gene Therapy (Upgrade)
- Market Voices: July Fed rate cut eyed, GLP-1s, Darden, Aflac, JPMorgan
- Obesity drugs should be among primary options to prevent heart disease: cardiology experts